Lignans Extracted from Eucommia Ulmoides Oliv. Protects Against AGEs-Induced Retinal Endothelial Cell Injury

Cell Physiol Biochem. 2016;39(5):2044-2054. doi: 10.1159/000447900. Epub 2016 Oct 31.

Abstract

Background/aims: Advanced glycation end products (AGEs) could elicit oxidative stress, trigger and aggravate endothelium damage in several ischemic retinopathies including diabetic retinopathy (DR). The leaves of Eucommia ulmoides O., also referred to as Tu-chung or Du-zhong, have been used for the treatment of hypertension and diabetes, showing great antioxidant activity and anti-glycation activity. Lignans is one of the main bioactive components of Eucommia ulmoides. This study mainly investigated the effect of lignans treatment on AGEs-induced endothelium damage.

Methods: MTT assay, Hoechst staining, and calcein-AM/ propidium iodide (PI) staining was conducted to determine the effect of lignans treatment on endothelial cell function in vitro. Retinal trypsin digestion, Evans blue assay, isolectin staining, and western blots were conducted to determine the effect of lignans treatment on retinal microvascular function in vivo. Western blot, protein immunoprecipitation (IP), MTT assays, and enzyme activity assay was conducted to detect the effect of ligans treatment on oxidative stress response.

Results: Lignans protected retinal endothelial cell against AGEs-induced injury in vitro and diabetes-induced vascular dysfunction in vivo. Lignans treatment could regulate oxidative stress response in retinal endothelial cell line, retina, and liver. Moreover, we showed that NRF2/HO-1 signaling was critical for lignans-mediated oxidative stress regulation.

Conclusion: Lignans treatment could protect against endothelial dysfunction in vivo and in vitro via regulating Nrf2/HO-1 signaling. Lignans might be developed as a promising drug for the treatment of diabetes-induced microvascular dysfunction.

MeSH terms

  • Animals
  • Blood-Retinal Barrier / drug effects
  • Blood-Retinal Barrier / metabolism
  • Cell Line
  • Cell Survival / drug effects
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / genetics
  • Diabetes Mellitus, Experimental / pathology
  • Diabetic Retinopathy / chemically induced
  • Diabetic Retinopathy / drug therapy*
  • Diabetic Retinopathy / genetics
  • Diabetic Retinopathy / pathology
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism
  • Endothelial Cells / pathology
  • Eucommiaceae / chemistry*
  • Evans Blue / metabolism
  • Gene Expression Regulation
  • Glycation End Products, Advanced / pharmacology*
  • Heme Oxygenase-1 / genetics
  • Heme Oxygenase-1 / metabolism
  • Hyperglycemia / chemically induced
  • Hyperglycemia / drug therapy*
  • Hyperglycemia / genetics
  • Hyperglycemia / pathology
  • Lignans / isolation & purification
  • Lignans / pharmacology*
  • Male
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism
  • Mice
  • Mice, Inbred C57BL
  • NF-E2-Related Factor 2 / genetics
  • NF-E2-Related Factor 2 / metabolism
  • Plant Extracts / chemistry
  • Plant Leaves / chemistry
  • Reactive Oxygen Species / antagonists & inhibitors
  • Reactive Oxygen Species / metabolism
  • Retina / drug effects
  • Retina / metabolism
  • Retina / pathology
  • Signal Transduction
  • Streptozocin

Substances

  • Glycation End Products, Advanced
  • Lignans
  • Membrane Proteins
  • NF-E2-Related Factor 2
  • Nfe2l2 protein, mouse
  • Plant Extracts
  • Reactive Oxygen Species
  • Evans Blue
  • Streptozocin
  • Heme Oxygenase-1
  • Hmox1 protein, mouse